

Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

1. (Canceled)
2. (Currently amended) ~~Method~~ A method for the treatment of multiple sclerosis, comprising administering to a patient in need of such treatment a pharmaceutical composition comprising a therapeutically effective amount of riluzole.
3. (Previously presented) The method of claim 2 wherein said pharmaceutical composition comprises a pharmaceutically effective carrier.
4. (Previously presented) The method of claim 2 wherein said pharmaceutical composition further comprises a therapeutically or prophylactically effective amount of an additional agent.
5. (Previously presented) The method of claim 4 wherein said additional agent is selected from the group consisting of interferon beta-1a, interferon beta-1b, and copaxone.
6. (Currently amended) ~~Method~~ The method according to claim 2 wherein ~~said composition~~ the amount of riluzole administered to the patient is administered in an amount of between about 10 and about 500 mg per day.
7. (Currently amended) The method of claim 6 wherein ~~said composition~~ the amount of riluzole administered to the patient is administered in an amount of between about 50 and about 250 mg per day.

8. (Currently amended) A method for treating a patient suffering from multiple sclerosis comprising the step of administering a pharmaceutical composition comprising riluzole in an amount effective to inhibit, minimize or delay the development of spinal cord atrophy associated with [[MS]] multiple sclerosis.

9. (Previously presented) The method of claim 8 wherein said pharmaceutical composition further comprises a therapeutically or prophylactically effective amount of an additional agent selected from the group consisting of interferon beta-lb, interferon beta-la, and copaxone.

10. (Currently amended) A method for the treatment of a patient suffering from [[MS]] multiple sclerosis comprising the steps of administering to said patient:

a. a therapeutically effective amount of a pharmaceutical composition comprising riluzole; and

b. a therapeutically effective amount of a pharmaceutical composition selected from the group consisting of interferon beta-lb, interferon beta-la, and copaxone.

11. (Currently amended) A method for the treatment of a patient suffering from primary progressive [[MS]] multiple sclerosis comprising administering to said patient a therapeutically effective amount of a pharmaceutical composition comprising riluzole.

12. (Previously presented) The method of claim 11 further comprising the administration of a therapeutically effective amount of interferon beta-lb, copaxone and interferon beta-la.

13. (Currently amended) A method for the treatment of a patient suffering from secondary-progressive [[MS]] multiple sclerosis comprising administering to said patient a therapeutically effective amount of a pharmaceutical composition comprising riluzole.

14. (Currently amended) A method for the treatment of a patient suffering from relapsing-remitting [[MS]] multiple sclerosis comprising administering to said patient a therapeutically effective amount of a pharmaceutical composition comprising riluzole.
15. (New) The method of claim 2, wherein the riluzole in the composition is 6-(trifluoromethoxy)-2-benzothiazolamine.
16. (New) The method of claim 2, wherein the riluzole in the composition is a salt of 6-(trifluoromethoxy)-2-benzothiazolamine.
17. (New) The method of claim 8, wherein the riluzole in the composition is 6-(trifluoromethoxy)-2-benzothiazolamine.
18. (New) The method of claim 8, wherein the riluzole in the composition is a salt of 6-(trifluoromethoxy)-2-benzothiazolamine.
19. (New) The method of claim 10, wherein the riluzole in the composition is 6-(trifluoromethoxy)-2-benzothiazolamine.
20. (New) The method of claim 10, wherein the riluzole in the composition is a salt of 6-(trifluoromethoxy)-2-benzothiazolamine.
21. (New) The method of claim 11, wherein the riluzole in the composition is 6-(trifluoromethoxy)-2-benzothiazolamine.
22. (New) The method of claim 11, wherein the riluzole in the composition is a salt of 6-(trifluoromethoxy)-2-benzothiazolamine.

23. (New) The method of claim 13, wherein the riluzole in the composition is 6-(trifluoromethoxy)-2-benzothiazolamine.
24. (New) The method of claim 13, wherein the riluzole in the composition is a salt of 6-(trifluoromethoxy)-2-benzothiazolamine.
25. (New) The method of claim 14, wherein the riluzole in the composition is 6-(trifluoromethoxy)-2-benzothiazolamine.
26. (New) The method of claim 14, wherein the riluzole in the composition is a salt of 6-(trifluoromethoxy)-2-benzothiazolamine.